Blog

- Andrew Celentano

Teaching the immune system to control HIV

There is no cure for HIV. While scientists have made considerable progress in controlling the infection, patients still must take daily antiretroviral medication for the rest of their lives. Results from a clinical trial led by Rockefeller, Imperial College London, and the University of Oxford (RIO) have offered a new strategy, suggesting that just one or two doses of broadly neutralizing antibodies (bNAbs) can suppress the virus long term, keeping it at undetectable levels for months and even years.

Read More »

Women experience less pain during IUD insertion using a new method

A simple method involving local anesthesia in the uterus can reduce pain during IUD insertion, according to a new study from Karolinska Institutet, published in the journal JAMA. The method also increased the proportion of women who found the procedure tolerable. The results may encourage more women to choose an IUD as a contraceptive method.

Read More »

Continuous glucose monitors may reveal hidden heart risk patterns in adults without diabetes

Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) are the clinical gold standards for screening blood sugar levels, yet they provide only static snapshots that fail to reflect the highly dynamic and heterogeneous nature of metabolic impairment. However, continuous glucose monitoring (CGM) is reshaping our understanding of these levels. While the medical community already has begun capitalizing on CGM for diabetes management, a new study has the potential to change current clinical practices for cardiovascular disease risk stratification in individuals without diabetes.

Read More »

A new AI-powered test offers more accurate prediction of breast cancer recurrence risk

A new study published in the journal npj Breast Cancer demonstrates that an artificial intelligence (AI) model offers more accurate predictions of recurrence risk in patients with early-stage breast cancer than the widely used 21-gene Recurrence Score. This research, conducted by a team from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences, specifically targets hormone receptor-positive (HR+) and HER2-negative disease, the most common subtype of breast cancer, which accounts for about half of all breast cancer cases in the United States.

Read More »